EIM
XENE icon

Essex Investment Management’s Xenon Pharmaceuticals XENE Stock Holding History

Essex Investment Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-70,172
Closed -$540K – 376
2016
Q4 		$540K Buy
+70,172
New +$564K 0.09% 240

Other funds holding XENE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
IPC
Invesco Private Capital New York $365M AUM 8.08% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Essex Investment Management's XENE Position: Q1 2017 in Review

Essex Investment Management sold out of Xenon Pharmaceuticals (XENE) in Q1 2017, closing a stake of 70,172 shares — an estimated $540K sold.

Essex Investment Management first reported a position in XENE in Q4 2016 and held it in 1 quarter. The position peaked at $540K in Q4 2016. 38 funds tracked by Wall St. Rank hold XENE as of Q1 2017.

  • Essex Investment Management reported no remaining Xenon Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Essex Investment Management sold 70,172 Xenon Pharmaceuticals shares in Q1 2017, an estimated $540K.
  • Essex Investment Management first reported a position in Xenon Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Essex Investment Management's Xenon Pharmaceuticals position peaked at $540K in Q4 2016.
  • 38 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q1 2017.

Based on Essex Investment Management's 13F filing for Q1 2017, filed 27 Apr 2017.